

# Real-world outcomes in refractory chronic graft-versus-host disease: the Italian multicenter experience with belumosudil

Francesca Bonifazi,<sup>1\*</sup> Marcello Roberto,<sup>1,2\*</sup> Maria Teresa Lupo Stanghellini,<sup>3</sup> Patrizia Chiusolo,<sup>4,5</sup> Nicola Polverelli,<sup>6</sup> Antonella Geromin,<sup>7</sup> Lucia Prezioso,<sup>8</sup> Mattia Algeri,<sup>9,10</sup> Giorgia Mancini,<sup>11</sup> Giulia Prunotto,<sup>12</sup> Alessandra Algarotti,<sup>13</sup> Chiara Nozzoli,<sup>14</sup> Michele Malagola,<sup>15</sup> Nicola Mordini,<sup>16</sup> Marilena Fedele,<sup>17</sup> Lidia Santoro,<sup>18</sup> Francesco Zallio,<sup>19</sup> Luca Castagna,<sup>20</sup> Alessandra Picardi,<sup>21,22</sup> Alessandro Busca,<sup>23</sup> Luisa Giaccone,<sup>24,25</sup> Cristina Skert,<sup>26</sup> Francesca Elice,<sup>27</sup> Luca Facchini,<sup>28</sup> Jacopo Mariotti,<sup>29</sup> Antonio Pierini,<sup>30</sup> Alessandro Spina,<sup>31</sup> Roberta De Marchi,<sup>32</sup> Dalila Salvatore,<sup>33</sup> Massimo Martino,<sup>34</sup> Manuela Tumino,<sup>35</sup> Alessandro Rambaldi<sup>13,36</sup> and Franco Locatelli<sup>9,37</sup>

<sup>1</sup>IRCCS Azienda Ospedaliero-Universitaria di Bologna, Istituto di Ematologia ‘Seràgnoli’, Bologna;

<sup>2</sup>Department of Medical and Surgical Sciences (DIMEC), University of Bologna, Bologna;

<sup>3</sup>Hematology and Bone Marrow Transplantation Unit, IRCCS San Raffaele Scientific Institute, Milan;

<sup>4</sup>Dipartimento di Scienze di Laboratorio ed Ematologiche, Fondazione Policlinico

Universitario Agostino Gemelli, IRCCS, Roma; <sup>5</sup>Dipartimento di Scienze Radiologiche ed

Ematologiche, Università Cattolica del Sacro Cuore, Roma; <sup>6</sup>Unit of Bone Marrow

Transplantation and Cellular Therapies, Division of Hematology, Fondazione IRCCS Policlinico

San Matteo, Pavia; <sup>7</sup>Division of Hematology and Stem Cell Transplantation, Azienda Sanitaria

Universitaria Friuli Centrale (ASUFC), Udine; <sup>8</sup>University Hospital of Parma - Hematology and

BMT Unit, Parma; <sup>9</sup>Department of Pediatric Hematology/Oncology and Cell and Gene Therapy,

IRCCS Bambino Gesù Children’s Hospital, Roma; <sup>10</sup>Department of Health Sciences, Magna

Græcia University, Catanzaro; <sup>11</sup>Clinic of Hematology, Azienda Ospedaliero Universitaria delle

Marche, Ancona; <sup>12</sup>Pediatric Hematology/Bone Marrow Transplantation Unit, Fondazione IRCCS

San Gerardo dei Tintori, Monza; <sup>13</sup>Department of Oncology and Hematology, Azienda Socio-

Sanitaria Territoriale Papa Giovanni XXIII, Bergamo; <sup>14</sup>Cell Therapy and Transfusion Medicine

Unit, Careggi University Hospital, Florence; <sup>15</sup>Chair of Hematology, University of Brescia; Adult

Bone Marrow Transplant Unit, Program of Cellular Therapy and Research in Hematology, ASST

Spedali Civili di Brescia, Brescia; <sup>16</sup>SC Ematologia, AO S. Croce e Carle Cuneo, Cuneo;

<sup>17</sup>Hematology Division, Fondazione IRCCS San Gerardo dei Tintori, Monza; <sup>18</sup>U.O.C. Ematologia e

Trapianto di Midollo Osseo, Avellino; <sup>19</sup>Stem Cell Transplant Unit, Hematology Division,

Alessandria; <sup>20</sup>BMT Unit, Azienda Ospedaliera Villa Sofia-Cervello, Palermo; <sup>21</sup>UOSC Ematologia

con Trapianto CSE e TI, AORN Cardarelli, Naples; <sup>22</sup>Department of Biomedicine and Prevention,

Tor Vergata University, Rome; <sup>23</sup>SS Trapianto Allogeneico Cellule Staminali, AOU Città della Salute

e della Scienza, Torino; <sup>24</sup>Division of Hematology, A.O.U. Città della Salute e della Scienza di

Torino, University of Torino, Torino; <sup>25</sup>Department of Molecular Biotechnology and Health

Sciences, University of Torino, Torino; <sup>26</sup>UOC Ematologia, Unità Trapianto Midollo Osseo,

Venezia; <sup>27</sup>Department of Hematology, San Bortolo Hospital, AULSS8 Berica, Vicenza;

<sup>28</sup>Hematology, Azienda USL IRCCS of Reggio Emilia, Reggio Emilia; <sup>29</sup>IRCCS Humanitas Research

Hospital, Rozzano; <sup>30</sup>Division of Hematology and Clinical Immunology, Department of Medicine,

University of Perugia, Perugia; <sup>31</sup>Reparto di Ematologia con Trapianto del Presidio Ospedaliero

‘A. Perrino’ di Brindisi, Brindisi; <sup>32</sup>Onco-Hematology, Department of Oncology, Veneto Institute

of Oncology IOV, IRCCS, Padova; <sup>33</sup>Unità di Terapia Intensiva Ematologica e Terapie Cellulari,

IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo; <sup>34</sup>Hematology and Stem Cell

Transplantation and Cellular Therapies Unit, Department of Hemato-Oncology and

Radiotherapy, Grande Ospedale Metropolitano ‘Bianchi-Melacrino-Morelli’, Reggio Calabria;

<sup>35</sup>Azienda Ospedale Università Padova, Padova; <sup>36</sup>Department of Oncology and Hematology,

University of Milan, Milan and <sup>37</sup>Catholic University of the Sacred Heart, Rome, Italy

**Correspondence:** F. Bonifazi

[francesca.bonifazi@unibo.it](mailto:francesca.bonifazi@unibo.it)

M. Roberto

[marcello.roberto2@unibo.it](mailto:marcello.roberto2@unibo.it)

**Received:** September 25, 2025.

**Accepted:** February 6, 2026.

**Early view:** February 19, 2026.

<https://doi.org/10.3324/haematol.2025.289302>

©2026 Ferrata Storti Foundation

Published under a CC BY-NC license



**Supplementary figure 1. Longitudinal assessment of Severity Index Score at 3, 6, and 12 months.**

Severity Index Score (SIS) for all patients (n = 80) at 3, 6, and 12 months relative to baseline. Each bar represents the individual patient score, categorized as NA (0), improvement (1;  $SIS \leq -2$ ), stability (2;  $SIS \pm 1$ ), or worsening (3;  $SIS \geq +2$ ). *NA: not available.* All patients (n = 80) are represented across the three time points (3, 6, and 12 months). Values on the x-axis vary according to the SIS, categorized as follows: 0=NA, 1=improvement ( $SIS \leq -2$ ), 2=stability.

Supplementary figure 1

SEVERITY INDEX SCORE

